abstract |
The application relates to the use of a β 3 adrenergicnreceptor agonist selected from the group consisting of formulasn(IV),(V),(VI),(VII) and (VIII)n n n n n nfor the manufacture of a medicament for the prophylactic and/or thentherapeutic treatment of dysuria. n In the above formulae, the various groups, substituents and variablesnhave the meanings given in the description. |